Keytruda Plus Standard Therapy Fails to Improve Outcomes in Multiple Myeloma
The addition of Keytruda (pembrolizumab) to standard therapy — Revlimid (lenalidomide) or Pomalyst (pomalidomide) in combination with dexamethasone…
News
Israeli Breakthroughs Credited for Early Progress in Treating Multiple Myeloma
Shlomit Norman was 42 when doctors diagnosed her with multiple myeloma — an incurable bone marrow cancer that rarely strikes people under the age…
FDA Grants Orphan Drug Designation to CARsgen’s CT053 for Multiple Myeloma Treatment
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to CT053, one of CARsgen Therapeutics’ lead CAR…
European Commission Approves Empliciti Triple Combo for Advanced Multiple Myeloma
The European Commission (EC) has approved Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone for the treatment…
GSK’s Belantamab Mafodotin Shows Promise for Relapsed or Refractory Multiple Myeloma
GlaxoSmithKline’s investigational antibody-drug conjugate, belantamab mafodotin (GSK2857916), demonstrated a clinically meaningful overall response rate in hard-to-treat multiple myeloma patients in a Phase…
Darzalex OK’d to Treat Multiple Myeloma Patients in Japan Not Eligible for Stem Cell Transplant
People in Japan newly diagnosed with multiple myeloma and ineligible for a stem cell transplant can now use a combination of Darzalex (daratumumab) and standard…
Kalytera’s Cannabidiol Prevents Graft-Versus-Host-Disease After Bone Marrow Transplant, Data Show
Kalytera’s cannabidiol (CBD) compound efficiently prevents graft-versus-host disease (GVHD) in patients receiving bone marrow transplants from matched unrelated donors, interim data from a Phase…
CAR T-cell Therapy Combo Shows Promise in Treating Advanced Multiple Myeloma, Study Says
Using a combination of CAR T-cell therapies to target different cancer molecules appears to be a feasible and promising way of treating relapsed or refractory…
Risk of Multiple Myeloma in People with MGUS Can Rise Over Time, Study Finds
People with monoclonal gammopathy of undetermined significance (MGUS) placed at low- or intermediate-risk of progression to multiple myeloma can develop that cancer within five…
Evomela Approved as Pre-transplant Conditioning Therapy for Multiple Myeloma Patients in China
Evomela, an injectable formulation of melphalan, is now available in China as a high-dose conditioning therapy for people with multiple myeloma who will…
